30th Jul 2009 11:00
AstraZeneca Development Pipeline
30 July 2009
Line Extensions
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Cardiovascular |
|||||
|
Atacand Plus |
angiotensin II antagonist/thiazide diuretic |
32/12.5 mg, 32/25 mg for hypertension |
III |
Launched |
|
|
Crestor |
statin |
outcomes in subjects with elevated CRP |
III |
Filed |
Filed |
|
Onglyza/ metformin FDC# |
DPP-4 inhibitor + biguanide FDC |
diabetes |
III |
1H 2010 |
4Q 2009 |
|
Dapagliflozin/ metformin FDC# |
SGLT2 inhibitor + biguanide FDC |
diabetes |
III |
2011 |
2011 |
|
Gastrointestinal |
|||||
|
Nexium |
proton pump inhibitor |
peptic ulcer bleeding |
III |
Launched |
Filed |
|
Axanum (Nexium low dose aspirin combination) |
proton pump inhibitor + low dose aspirin |
low dose aspirin associated peptic ulcer |
III |
1H 2010** |
Filed |
|
Nexium |
proton pump inhibitor |
extra-oesophageal reflux disease |
II |
Published* |
Published* |
|
Neuroscience |
|||||
|
Seroquel |
D2/5HT2 antagonist |
bipolar maintenance |
III |
Filed |
Launched |
|
Seroquel |
D2/5HT2 antagonist |
bipolar depression |
III |
Launched |
Launched |
|
Seroquel XR |
D2/5HT2 antagonist |
major depressive disorder |
III |
Filed |
Filed |
|
Seroquel XR |
D2/5HT2 antagonist |
bipolar mania |
III |
Launched |
Launched |
|
Seroquel XR |
D2/5HT2 antagonist |
bipolar depression |
III |
Launched |
Launched |
|
Seroquel XR |
D2/5HT2 antagonist |
generalised anxiety disorder |
III |
Filed |
Filed |
|
Oncology & Infection |
|||||
|
FluMist |
live, attenuated, intranasal influenza virus vaccine |
influenza |
III |
Filed |
Launched |
|
Iressa |
EGFR tyrosine kinase inhibitor |
NSCLC |
III |
Launched |
|
|
Zactima |
VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity |
medullary thyroid cancer |
III |
2H 2010 |
1H 2010 |
|
Faslodex |
oestrogen receptor antagonist |
first line advanced breast cancer |
III |
||
|
Faslodex |
oestrogen receptor antagonist |
high dose (500mg) second line advanced breast cancer |
III |
4Q 2009 |
1H 2010 |
|
Motavizumab |
humanized MAb binding to RSV F protein |
early and late treatment of RSV in paeds >1 yr |
II |
2015 |
|
*Publication only
**Previously submission was indication-only. Now covers fixed dose combination.
#Partnered product
Line Extensions (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Respiratory & Inflammation |
|||||
|
Symbicort pMDI |
inhaled steroid/fast onset, long-acting β2 agonist |
asthma |
III |
Filed |
Launched* |
|
Symbicort pMDI |
inhaled steroid/fast onset, long-acting β2 agonist |
COPD |
III |
Filed |
Launched |
*US approval based on 12 years and above.
NCEs
Phase III/Registration
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Cardiovascular |
|||||
|
Onglyza# |
DPP-4 inhibitor |
diabetes |
III |
Filed |
Filed |
|
Brilinta |
ADP receptor antagonist |
arterial thrombosis |
III |
4Q 2009 |
4Q 2009 |
|
Certriad# (Crestor/TriLipix) |
statin + fibrate fixed combination |
dyslipidaemia |
III |
Filed |
|
|
Dapagliflozin# |
SGLT2 inhibitor |
diabetes |
III |
2H 2010 |
2H 2010 |
|
Neuroscience |
|||||
|
Vimovo# (PN400) |
naproxen + esomeprazole |
signs and symptoms of OA, RA and AS |
III |
4Q 2009 |
Filed |
|
Oncology & Infection |
|||||
|
Motavizumab |
humanized MAb binding to RSV F protein |
RSV prevention |
III |
2H 2010 |
Filed |
|
Zactima |
VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity |
NSCLC |
III |
Filed |
Filed |
|
Recentin |
VEGFR tyrosine kinase inhibitor |
CRC |
III |
2H 2010 |
2H 2010 |
|
Recentin |
VEGFR tyrosine kinase inhibitor |
recurrent glioblastoma |
III |
2H 2010 |
2H 2010 |
|
ZD4054 |
endothelin A receptor antagonist |
hormone resistant prostate cancer |
III |
2011 |
2011 |
#Partnered product
NCEs
Phases I and II
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Cardiovascular |
|||||
|
AZD0837 |
direct thrombin inhibitor |
thrombosis |
II |
||
|
AZD1305 |
antiarrhythmic |
arrhythmias |
II |
||
|
AZD6370 |
GK activator |
diabetes |
II |
||
|
AZD1656 |
GK activator |
diabetes/obesity |
II |
||
|
AZD6482 |
PI3K-beta inhibitor |
thrombosis |
I |
||
|
AZD4017 |
11BHSD inhibitor |
diabetes/obesity |
I |
||
|
AZD6714 |
GK activator |
diabetes/obesity |
I |
||
|
Gastrointestinal |
|||||
|
AZD3355 |
inhibitor of transient lower oesophageal sphincter relaxations (TLESR) |
GERD |
II |
2013 |
2013 |
|
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
GERD |
I |
||
|
AZD1386 |
vanilloid receptor antagonist |
GERD |
I |
||
NCEs
Phases I and II (continued)
|
Neuroscience |
|||||
|
AZD3480# |
Alpha4/beta2 neuronal nicotinic receptor agonist |
ADHD |
II |
||
|
AZD6765 |
NMDA receptor antagonist |
major depressive disorder |
II |
2012 |
2012 |
|
AZD1386 |
vanilloid receptor antagonist |
chronic nociceptive pain |
II |
||
|
AZD2327 |
enkephalinergic receptor modulator |
anxiety and depression |
II |
||
|
AZD7325 |
GABA receptor subtype partial agonist |
anxiety |
II |
2013 |
2012 |
|
AZD4694 |
FNAPD-1 |
Alzheimer's disease PET diagnostic |
II |
||
|
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
chronic neuropathic pain |
II |
||
|
AZD8529 |
glutamatergic modulator |
schizophrenia |
II |
||
|
AZD5904 |
myeloperoxidase (MPO) inhibitor |
multiple sclerosis |
I |
||
|
AZD3241 |
myeloperoxidase (MPO) inhibitor |
Parkinson's disease |
I |
||
|
AZD6280 |
GABA receptor subtype partial agonist |
anxiety |
I |
||
|
TC-5619# |
Alpha7 neuronal nicotinic receptor agonist |
cognitive disorders in schizophrenia |
I |
||
|
AZD2516 |
metabotropic glutamate receptor 5 antagonist |
chronic neuropathic pain |
I |
||
|
AZD1446# |
Alpha4/beta2 neuronal nicotinic receptor agonist |
Alzheimer's disease/ADHD |
I |
||
|
AZD7268 |
enkephalinergic receptor modulator |
depression/anxiety |
I |
||
|
AZD3043# |
GABA-A receptor modulator |
short-acting anaesthetic |
I |
||
|
AZD6088 |
muscarinic M1 receptor agonist |
chronic neuropathic pain |
I |
||
|
AZD2423 |
chemokine antagonist |
chronic neuropathic pain |
I |
||
#Partnered product
NCEs
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Oncology & Infection |
|||||
|
Recentin |
VEGFR tyrosine kinase inhibitor |
NSCLC |
II |
2013 |
2013 |
|
CytoFab# |
anti-TNF-alpha polyclonal antibody |
severe sepsis |
II |
||
|
AZD6244# (ARRY-142886) |
MEK inhibitor |
solid tumours |
II |
2014 |
2014 |
|
Olaparib (AZD2281) |
PARP inhibitor |
breast/ovarian cancer |
II |
2012 |
2012 |
|
Saracatinib (AZD0530) |
SRC kinase inhibitor |
solid tumours |
II |
2012 |
2012 |
|
AZD7295 |
NS 5a inhibitor |
hepatitis C |
II |
||
|
AZD1152 |
aurora kinase inhibitor |
haematological malignancies |
II |
2011 |
2011 |
|
MEDI-3250 |
flu vaccine (quadravalent) |
seasonal influenza |
II |
||
|
AZD4769 |
EGFR tyrosine kinase inhibitor |
solid tumours |
I |
||
|
AZD8931 |
erbB kinase inhibitor |
solid tumours |
I |
||
|
AZD7762 |
CHK1 kinase Inhibitor |
solid tumours |
I |
||
|
AZD8330# (ARRY-424704) |
MEK inhibitor |
solid tumours |
I |
||
|
CAT-8015 |
recombinant immunotoxin |
haematological malignancies |
I |
||
|
MEDI-534 |
RSV/PIV-3 vaccine |
RSV/PIV prophylaxis |
I |
||
|
MEDI-560 |
PIV-3 vaccine |
intranasal immunisation |
I |
||
|
MEDI-550* (MEDI-566) |
pandemic influenza virus vaccine |
pandemic influenza vaccine |
I |
||
|
AZD9639# (MEDI-564) |
RSV F protein inhibitor |
RSV treatment |
I |
||
|
CMV Vaccine |
CMV vaccine |
cytomegalovirus |
I |
||
|
MEDI-557 |
YTE - extended half-life RSV MAb |
RSV prophylaxis |
I |
||
|
AZD8055 |
TOR kinase inhibitor |
range of tumours |
I |
||
|
MEDI-559 |
RSV vaccine |
RSV prophylaxis |
I |
||
|
MEDI-573 |
IGF |
solid tumours |
I |
||
|
MEDI-575 |
PDGFR-alpha |
solid tumours |
I |
||
|
AZD1480 |
JAK2 inhibitor |
myeloproliferative diseases |
I |
||
*MEDI-550 is a library of vaccines and MEDI-566 was one strain that is no longer active
#Partnered product
NCEs
Phases I and II (continued)
|
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
|
MAA |
NDA |
||||
|
Respiratory & Inflammation |
|||||
|
AZD1981 |
CRTh2 receptor antagonist |
asthma/COPD |
II |
||
|
MEDI-528 |
anti-IL-9 antibody |
asthma |
II |
||
|
CAT-354 |
anti-IL-13 antibody |
asthma |
II |
||
|
AZD9668 |
neutrophil elastase inhibitor |
COPD |
II |
||
|
AZD1236 |
matrix metallo-proteinase inhibitor |
COPD |
II |
||
|
AZD3199 |
iLABA |
asthma/COPD |
II |
||
|
MEDI-563 |
anti-IL-5R antibody |
asthma |
II |
||
|
MEDI-545 |
anti-IFN-alpha antibody |
SLE, myositis |
II |
||
|
CAM-3001 |
anti-GM-CSFR |
rheumatoid arthritis |
I |
||
|
AZD8848 |
asthma |
I |
|||
|
AZD8566 |
CCR5 |
rheumatoid arthritis |
I |
||
|
AZD8075 |
CRTh2 antagonist |
asthma/COPD |
I |
||
|
AZD5985 |
CRTh2 antagonist |
asthma/COPD |
I |
||
|
AZD9164 |
LAMA |
COPD |
I |
||
|
AZD2551 |
protease inhibitor |
COPD |
I |
||
AstraZeneca Development Pipeline
Discontinued Projects vs 29 January 2009 FY
Neuroscience
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD1940 |
nociceptive and neuropathic pain |
|
NCE |
AZD2624 |
schizophrenia |
Oncology & Infection
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD6918 |
solid tumours |
|
NCE |
MEDI-538 |
leukaemia/lymphoma |
|
NCE |
AZD4877 |
haematological malignancies |
|
Faslodex |
oestrogen receptor antagonist |
adjuvant |
Respiratory & Inflammation
|
NCE/Line Extension |
Compound |
Area Under Investigation |
|
NCE |
AZD9056 |
RA |
|
NCE |
AZD5672 |
RA |
|
Unit Dose Budesonide |
inhaled steroid |
asthma |
Comments
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Compounds in development are displayed by phase.
Key:
MAA - Marketing Authorisation Application (Europe).
NDA - New Drug Application/Biologics Licensing Application (USA).
Related Shares:
Astrazeneca